BMS 182248

Known as: BMS-182248 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2000
0119942000

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
PURPOSE High levels (> 200,000 molecules per carcinoma cell) of the LewisY antigen are expressed on the surface of most (> 75… (More)
Is this relevant?
1997
1997
Purpose: The chimeric BR96–doxorubicin (DOX) immunoconjugate, BMS 182248, has induced remissions and cures of human lung… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
1994
1994
The toxicity of BMS-182248, an immunoglobulin (cBR96)-cytotoxic drug (doxorubicin) conjugate, was investigated in Sprague-Dawley… (More)
Is this relevant?